Unichem Laboratories ANDA approval for Divalproex Sodium Extended-Release Tablets

Unichem Laboratories Limited has received ANDA approval for its Divalproex Sodium Extended-Release Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Depakote® ER (Divalproex Sodium) Extended-Release Tablets 250 mg and 500 mg, of AbbVie Inc.

Divalproex Sodium Extended-Release Tablets are indicated for treatment of acute manic or mixed episodes associated with bipolar disorder, as monotherapy and adjunctive therapy and prophylaxis of migraine headaches. The product will be commercialized from Unichem's Goa Plant.

Shares of Unichem Laboratories Limited was last trading in BSE at Rs. 258.45 as compared to the previous close of Rs. 238.20. The total number of shares traded during the day was 37993 in over 3506 trades.

The stock hit an intraday high of Rs. 260.35 and intraday low of 236.00. The net turnover during the day was Rs. 9478526.00.

Source : Equity Bulls

Keywords

UnichemLaboratories INE351A01035 ANDAApproval USFDA DivalproexSodium ExtendedReleaseTablets